Type of Study:
This is a study of the Exeltis Birth Control Pill which is allowed while breastfeeding.

Study Length:
14-Months - Potentially a 12-month extension (extension is optional).

Target Age/Sex:
18 to 45 years, Female

Benefits:
Participants will receive at no cost: Study medication and study related procedures. Participants may also receive a stipend for time/travel related to the study.

Link: ClinicalTrials.gov

Staus: Enrolling

Description:

The purpose of this study is to test the efficacy, safety, and tolerability of LPRI-CF113 as an oral contraceptive in females.

Potential participants must be sexually active and engage in heterosexual vaginal intercourse at least once per month with a partner who is not known to be subfertile, sterilized, or infertile, and should not routinely use any other form of contraception.

To learn more, fill out the form or call 208-557-2991 or 208-557-2924.

 

Information Request

Information Request

How did you hear about this study?